News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
569,071 Results
Type
Article (47706)
Company Profile (120)
Press Release (521233)
Multimedia
Podcasts (141)
Webinars (19)
Section
Business (150812)
Career Advice (2437)
Deals (28755)
Drug Delivery (141)
Drug Development (72185)
Employer Resources (158)
FDA (16041)
Job Trends (12262)
News (274898)
Policy (30238)
Tag
2027 Biotech Bay Standard (1)
2027 Genetown Elite (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2352)
Academic (1)
Accelerated approval (34)
Adcomms (36)
Allergies (135)
Alliances (38380)
ALS (166)
Alzheimer's disease (1718)
Antibody-drug conjugate (ADC) (312)
Approvals (16184)
Artificial intelligence (500)
Autoimmune disease (157)
Automation (33)
Bankruptcy (316)
Best Places to Work (9358)
BIOSECURE Act (23)
Biosimilars (191)
Biotechnology (73)
Bladder cancer (157)
Brain cancer (55)
Breast cancer (587)
Cancer (4545)
Cardiovascular disease (409)
Career advice (2061)
Career pathing (39)
CAR-T (258)
CDC (59)
Celiac Disease (1)
Cell therapy (718)
Cervical cancer (35)
Clinical research (61614)
Collaboration (1504)
Company closure (4)
Compensation (1150)
Complete response letters (73)
COVID-19 (2738)
CRISPR (86)
C-suite (778)
Cystic fibrosis (144)
Data (5805)
Decentralized trials (2)
Denatured (32)
Depression (144)
Diabetes (487)
Diagnostics (5564)
Digital health (35)
Diversity (7)
Diversity, equity & inclusion (43)
Drug discovery (231)
Drug pricing (221)
Drug shortages (33)
Duchenne muscular dystrophy (235)
Earnings (63528)
Editorial (65)
Employer branding (20)
Employer resources (142)
Events (84510)
Executive appointments (892)
FDA (19106)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (11)
Frontotemporal dementia (21)
Funding (1283)
Gene editing (191)
Generative AI (45)
Gene therapy (607)
GLP-1 (1085)
Government (4205)
Grass and pollen (8)
Guidances (378)
Healthcare (15017)
HIV (58)
Huntington's disease (49)
IgA nephropathy (84)
Immunology and inflammation (287)
Immuno-oncology (58)
Indications (95)
Infectious disease (2995)
Inflammatory bowel disease (185)
Inflation Reduction Act (14)
Influenza (107)
Intellectual property (235)
Interviews (456)
IPO (14312)
IRA (57)
Job creations (3213)
Job search strategy (1684)
JPM (67)
Kidney cancer (16)
Labor market (81)
Layoffs (619)
Leadership (39)
Legal (7111)
Liver cancer (90)
Longevity (12)
Lung cancer (599)
Lymphoma (354)
Machine learning (40)
Management (52)
Manufacturing (739)
MASH (168)
Medical device (11636)
Medtech (11680)
Mergers & acquisitions (15443)
Metabolic disorders (1325)
Multiple sclerosis (146)
NASH (22)
Neurodegenerative disease (324)
Neuropsychiatric disorders (98)
Neuroscience (2929)
Neurotech (1)
NextGen: Class of 2026 (5069)
Non-profit (3217)
Now hiring (30)
Obesity (663)
Opinion (282)
Ovarian cancer (152)
Pain (190)
Pancreatic cancer (215)
Parkinson's disease (278)
Partnered (27)
Patents (482)
Patient recruitment (453)
Peanut (54)
People (45404)
Pharmaceutical (33)
Pharmacy benefit managers (32)
Phase 1 (18798)
Phase 2 (26776)
Phase 3 (21342)
Pipeline (4968)
Policy (332)
Postmarket research (2257)
Preclinical (7866)
Press Release (28)
Prostate cancer (242)
Psychedelics (56)
Radiopharmaceuticals (250)
Rare diseases (880)
Real estate (4432)
Recruiting (65)
Regulatory (23392)
Reports (42)
Research institute (2152)
Resumes & cover letters (406)
Rett syndrome (27)
RNA editing (16)
RSV (72)
Schizophrenia (152)
Series A (219)
Series B (178)
Service/supplier (8)
Sickle cell disease (95)
Special edition (25)
Spinal muscular atrophy (158)
Sponsored (46)
Startups (2954)
State (1)
Stomach cancer (20)
Supply chain (106)
Tariffs (101)
The Weekly (108)
Vaccines (1089)
Venture capital (95)
Weight loss (466)
Women's health (73)
Worklife (22)
Date
Today (118)
Last 7 days (544)
Last 30 days (2056)
Last 365 days (28453)
2026 (2942)
2025 (28655)
2024 (31773)
2023 (35412)
2022 (45659)
2021 (49256)
2020 (46179)
2019 (36930)
2018 (28023)
2017 (28529)
2016 (26587)
2015 (29130)
2014 (22764)
2013 (18738)
2012 (19952)
2011 (20481)
2010 (18575)
Location
Africa (702)
Alabama (67)
Alaska (6)
Arizona (231)
Arkansas (11)
Asia (33417)
Australia (5999)
California (10424)
Canada (2578)
China (921)
Colorado (409)
Connecticut (456)
Delaware (304)
Europe (81546)
Florida (1569)
Georgia (316)
Hawaii (4)
Idaho (40)
Illinois (741)
India (54)
Indiana (427)
Iowa (22)
Japan (404)
Kansas (105)
Kentucky (27)
Louisiana (19)
Maine (75)
Maryland (1285)
Massachusetts (7572)
Michigan (265)
Minnesota (567)
Mississippi (5)
Missouri (117)
Montana (17)
Nebraska (22)
Nevada (110)
New Hampshire (61)
New Jersey (2805)
New Mexico (15)
New York (2694)
North Carolina (1350)
North Dakota (7)
Northern California (5154)
Ohio (280)
Oklahoma (16)
Oregon (34)
Pennsylvania (2019)
Puerto Rico (17)
Rhode Island (32)
South America (1064)
South Carolina (63)
South Dakota (1)
Southern California (4071)
Tennessee (149)
Texas (1556)
United States (36503)
Utah (264)
Virginia (243)
Washington D.C. (73)
Washington State (829)
West Virginia (4)
Wisconsin (109)
Wyoming (1)
569,071 Results for "leiter s compounding".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Legal
Compounder Sues Lilly, Novo, Claims Coordinated Crackdown
Strive Compounding Pharmacy alleged in its lawsuit that Eli Lilly and Novo Nordisk have worked to lock telehealth providers in exclusive partnerships, disallowing them from offering compounded versions of GLP-1 medicines.
January 15, 2026
·
2 min read
·
Tristan Manalac
Regulatory
Hims & Hers’ Woes Compound as FDA Hits Company With Warning Letter
The agency flagged several violations at a compounding pharmacy owned by Hims & Hers, including “infestation by rodents, birds insects, and other vermin.”
February 10, 2026
·
2 min read
·
Tristan Manalac
GLP-1
Makary Blasts ‘Illegal Copycat Drugs’ as Hims Launches Compounded Wegovy Pill
Novo Nordisk has also spoken out strongly against Hims & Hers’ compounded Wegovy pill, with CEO Maziar Mike Doustdar telling investors the knockoff version is a waste of money.
February 6, 2026
·
1 min read
·
Tristan Manalac
Press Releases
Novo Nordisk A/S: China’s Supreme People’s Court delivers a positive ruling on the semaglutide compound patent
January 1, 2026
·
2 min read
Press Releases
GRI Bio Secures New U.S. Composition of Matter Patent Covering Novel Compound Structures
January 27, 2026
·
6 min read
GLP-1
Novo Sues Hims & Hers Over Compounded Version of Oral Wegovy Pill
Novo Nordisk has sued Hims for allegedly violating patents protecting semaglutide, seeking potentially “hundreds of millions” in damages, John Kuckelman, the pharma’s general counsel, said. The wellness platform pulled its version of the drug just days after launching it.
February 9, 2026
·
2 min read
·
Tristan Manalac
FDA
FDA Demurs on GLP-1 Compounding Fight, Debuts Consumer ‘Green List’ Instead
While a win for consumers, the regulatory action did nothing to stem the manufacture of compounded versions of the popular obesity drugs that are made by Novo Nordisk and Eli Lilly. In fact, the FDA seems to be signaling that “some level of compounded product is acceptable,” according to BMO Capital Markets.
September 8, 2025
·
2 min read
·
Annalee Armstrong
FDA
FDA Takes Long Overdue Baby Step Toward Regulating Compounder Drug Ads
A complex state vs. federal regulatory scheme allows drug compounders to advertise drugs without disclosing risks like a pharma company must do. Experts say it’s time for the FDA to crack down.
September 17, 2025
·
7 min read
·
Annalee Armstrong
Press Releases
Kiora Pharmaceuticals Granted U.S. Patent Covering Additional Formulations for the KIO-100 Family of Anti-Inflammatory Compounds
December 1, 2025
·
4 min read
Press Releases
Quva Awarded National Outsourced Compounded Preparations Agreement with Premier, Inc.
January 7, 2026
·
2 min read
1 of 56,908
Next
